These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 22634534)
1. Biological markers of cisplatin resistance in advanced testicular germ cell tumours. García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534 [TBL] [Abstract][Full Text] [Related]
2. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200 [TBL] [Abstract][Full Text] [Related]
3. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898 [TBL] [Abstract][Full Text] [Related]
4. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802 [TBL] [Abstract][Full Text] [Related]
5. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254 [TBL] [Abstract][Full Text] [Related]
8. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment. Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521 [TBL] [Abstract][Full Text] [Related]
9. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something? Ottaviano M; Giunta EF; Rescigno P; Pereira Mestre R; Marandino L; Tortora M; Riccio V; Parola S; Casula M; Paliogiannis P; Cossu A; Vogl UM; Bosso D; Rosanova M; Mazzola B; Daniele B; Palmieri G; Palmieri G Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281219 [TBL] [Abstract][Full Text] [Related]
10. P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. Baltaci S; Orhan D; Türkölmez K; Yesilli C; Bedük Y; Tulunay O BJU Int; 2001 May; 87(7):661-6. PubMed ID: 11350408 [TBL] [Abstract][Full Text] [Related]
11. Association between glutathione S-transferases M1 expression and treatment outcome in germ cell tumor patients. Mego M; Kalavska K; Horak S; Hyblova M; Kolnikova G; Novotna V; Majtanova K; Minarik G; Kucerova L; Cierna Z Neoplasma; 2024 Aug; 71(4):374-386. PubMed ID: 39267534 [TBL] [Abstract][Full Text] [Related]
12. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1. Pectasides D; Papaxoinis G; Nikolaou M; Valavanis C; Aravantinos G; Fountzilas G; Tamvakis N; Pectasides E; Lekka I; Arapantoni-Dadioti P; Zizi A; Ghiconti I; Economopoulos T Anticancer Res; 2009 Feb; 29(2):737-44. PubMed ID: 19331230 [TBL] [Abstract][Full Text] [Related]
13. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours. Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610 [TBL] [Abstract][Full Text] [Related]
14. Genomic evolution and chemoresistance in germ-cell tumours. Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446 [TBL] [Abstract][Full Text] [Related]
15. The Role of Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin‑resistant germ cell tumor models: An exploration of the epithelial‑mesenchymal transition regulator Cardoso IIV; Rosa MN; Moreno DA; Tufi LMB; Ramos LP; Pereira LAB; Silva L; Galvão JMS; Tosi IC; Lengert AVH; Da Cruz MC; Teixeira SA; Reis RM; Lopes LF; Pinto MT Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39392037 [TBL] [Abstract][Full Text] [Related]
17. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363 [TBL] [Abstract][Full Text] [Related]
18. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines. Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996 [TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576 [TBL] [Abstract][Full Text] [Related]